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Induced costimulatory ligand (ICOSL) plays an important role in the activation of T cells 
through its interaction with the inducible costimulator, ICOS. Suppression of full T cell 
activation can be achieved by blocking this interaction and has been shown to be an 
effective means of ameliorating disease in models of autoimmunity and inflammation. In 
this study, we demonstrated the ability of a novel class of anti-ICOSL antigen-binding 
 single domains derived from sharks (VNARs) to effectively reduce inflammation in a
murine model of non-infectious uveitis. In initial selections, specific VNARs that rec-
ognized human ICOSL were isolated from an immunized nurse shark phage display
library and lead domains were identified following their performance in a series of antigen 
selectivity and in  vitro bioassay screens. High potency in cell-based blocking assays
suggested their potential as novel binders suitable for further therapeutic development. 
To test this hypothesis, surrogate anti-mouse ICOSL VNAR domains were isolated from 
the same phage display library and the lead VNAR clone selected via screening in bind-
ing and ICOS/ICOSL blocking experiments. The VNAR domain with the highest potency 
in cell-based blocking of ICOS/ICOSL interaction was fused to the Fc portion of human 
IgG1 and was tested in vivo in a mouse model of interphotoreceptor retinoid-binding 
protein-induced uveitis. The anti-mICOSL VNAR Fc, injected systemically, resulted in a 
marked reduction of inflammation in treated mice when compared with untreated control 
animals. This approach inhibited disease progression to an equivalent extent to that
seen for the positive corticosteroid control, cyclosporin A, reducing both clinical and
histopathological scores. These results represent the first demonstration of efficacy of a 
VNAR binding domain in a relevant clinical model of disease and highlight the potential 
of VNARs for the treatment of auto-inflammatory conditions.
 
 
 
 
 
Keywords: variable domain of shark new antigen receptor, single chain binding domain, shark, autoimmunity, 
phage display, biologic therapeutics, uveitis
Abbreviations: IgNAR, immunoglobulin like new antigen receptor; VNAR, variable domain of shark new antigen receptor; 
ICOSL, induced costimulatory ligand; CDR, complementarity determining region; FW, framework; HV, hypervariable region; 
IRBP, interphotoreceptor retinoid-binding protein; EAU, experimental autoimmune uveitis; APC, antigen-presenting cell.
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inTrODUcTiOn
Inflammatory eye disease, uveitis, is a significant but largely 
unrecognized cause of visual impairment, characterized by 
a very rapid and debilitating inflammation of the uvea (the 
pigmented and vascular structures of the eye) and requires 
immediate diagnosis and treatment to prevent partial or total 
and irreversible loss of sight. In the Western world, current inci-
dences vary between 38 and 200 per 100,000 and it is estimated 
to be 730 per 100,000 in India (1). The proportion of people 
suffering marked visual loss may be as high as 35% with over 
30,000 people in the US annually becoming blind (2, 3). Non-
infectious uveitis, which is 70% of the total cases presented, is 
predominantly an acute manifestation of an underlying chronic 
autoimmune condition, and T cell activation plays a critical role 
in its pathogenesis (4).
There is currently no curative therapy and available treatments 
aim at reducing the inflammation and managing the symptoms. 
First-line approaches consist of corticosteroids that are often 
used with anti-metabolites and alkylating agents (5). For the 50% 
of patients who respond well, corticosteroids are inexpensive, 
potent and rapidly effective. However, around 30% of patients do 
not respond to this form of immunomodulation and the rest often 
suffer significant side effects, including glaucoma and cataracts, 
which trigger a rapid termination of therapy. Corticosteroid side 
effects become increasingly common as uveitis episodes recur.
When ocular inflammatory disease cannot be controlled with 
conventional immunosuppressive drugs (refractory patients), 
systemically administered adalimumab (Humira) is the most 
common anti-TNF-α (anti-inflammatory) agent used clinically 
(6). Humira completed a Phase 3 study in 2015 and reported a 
significant period of improvement in refractory patients from an 
average of 3–5.6 months and a reduction in the risk of “vision 
loss”. The product was approved by the FDA in 2016 for posterior 
uveitis (7–9). While many patients benefited from anti-TNF 
therapy, a significant number reported serious side effects with 
prolonged systemic administration considered the most probable 
cause of the adverse events recorded.
Shark Ig novel antigen receptors (IgNARs) are naturally 
occurring binding proteins known to play a role in the adaptive 
immune system of cartilaginous fish (10, 11). While IgNARs 
perform many of the duties of antibodies they have a differ-
ent ancestral origin and structural architecture. IgNARs have 
never had, or lost, a light chain partner and have squeezed an 
additional binding loop into the single domain format of their 
two variable binding sites VNARs. An important aspect of their 
function is the ability to specifically bind with high affinity to 
target, achieved using four regions of high sequence diversity: 
complementarity determining region (CDR) 1, hypervariable 
region (HV) 2, HV4 and CDR3 (12, 13). In some species of shark 
non-canonical cysteine residues create an additional repertoire 
of VNAR isotypes that translate into structurally distinct fami-
lies with diverse paratope topologies capable of binding more 
cryptic or hidden epitopes (13, 14). The combination of a lack 
of light chain partner and CDR2 makes VNARs the smallest 
naturally occurring binding domains in the vertebrate kingdom. 
This, in addition to their exquisite selectivity for target, inherent 
solubility and stability, makes them attractive candidates for 
therapeutic drug and diagnostic development (15–17).
It has been previously demonstrated by Dooley and Flajnik 
(18) that along with monomeric IgM, sharks can produce an 
antigen-specific IgNAR response following immunization. 
Libraries of VNARs from immunized sharks have been con-
structed and positive clones with high affinity and specificity to 
different targets like HSA, HEL, TNFα and Ebola virus have been 
isolated (19). In this work, phage display technology was utilized 
to isolate VNARs from an immunized shark library, which target 
and neutralize the induced costimulatory ligand (ICOSL).
ICOSL—also known as B7-related protein (B7RP-1), CD275, 
and B7 homolog (B7h)—is a cell surface antigen expressed 
constitutively on antigen-presenting cells (APCs) such as B cells, 
activated monocytes and dendritic cells, and is the ligand for the 
B7 family member, inducible costimulator (ICOS; CD278) (20). 
Initially, it was believed that its action was restricted to activation 
of T cells but more recently the central role of ICOSL in immune 
modulation has been expanded to both T  cell stimulatory and 
inhibitory pathways through its interaction with CD28 and 
CTLA4, respectively (21). The generation of transgenic mice 
with lineage-restricted ICOSL expression has demonstrated the 
role of ICOSL–ICOS interaction in stimulating T cell responses, 
T cell tolerance and T cell-dependent B cell responses (22–24). 
The role of the ICOS/ICOSL pathway and ICOSL as a possible 
drug target has been previously validated in murine experimental 
autoimmune uveoretinitis (25). Here, we describe the isolation 
and characterization of VNAR domains that bind and neutral-
ize ICOSL in a dose-dependent manner and provide the first 
evidence of the therapeutic potential of shark VNAR domains in 
a clinical model of disease. The experimental autoimmune uveitis 
(EAU) model of choice for this study was an interphotoreceptor 
retinoid-binding protein (IRBP)-induced uveitis in mice, which 
is considered to mirror many of the histological and clinical 
hallmarks of uveitis in humans (26, 27). While this study reports 
the benefits of systemically delivered VNAR Fc molecules, it is 
hoped that the progress seen here will become a stepping stone to 
the site-specific delivery of small, soluble and efficacious VNAR 
domains directly into the eye, combining the potency of biologics 
therapy with reduced systemic side effects.
MaTerials anD MeThODs
shark immunization
Nurse sharks (Ginglymostoma cirratum) were placed in contain-
ers filled with artificial sea water containing 0.1% (w/v) tricaine 
methanesulfonate (MS-222). When the desired level of narcosis 
was reached, they were removed for immunization or bleeding. 
Recombinant in-house CHO-expressed mouse and human 
ICOSL-flag-His (200 μg/shark) emulsified in complete Freund’s 
adjuvant (CFA) were injected using a 20 gauge needle into the 
lateral fin of the shark. Four weeks later, antigens (200 μg/shark) 
emulsified in incomplete Freund’s adjuvant were similarly admin-
istered to the shark. Three immunization boosts (100 μg/shark) 
were given at 4-week intervals intravenously into the caudal vein 
as soluble antigen in PBS (sample 0.45 µM sterile filtered). Between 
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3 and 5 ml of blood samples were collected from the caudal vein 
into a 30 ml syringe containing 200 µl porcine heparin (1,000 U/
ml in PBS) at weeks 0 (pre-immunization bleed), 10, 14, 18 and 
22. Blood samples were spun at 1,000 × g for 10 min to separate 
blood cells from plasma. The plasma supernatant fraction was 
carefully removed into a sterile tube with RNA stabilization buffer 
and stored at −80°C.
serum ignar Titer elisa
Immunoplates (Nunc, Thermo Scientific) were coated overnight 
at 4°C with 1 µg/ml human or murine ICOSL and then blocked 
with 4% (w/v) milk PBS (MPBS) for 2 h at 37°C. Shark serum 
was diluted 1:30 and then a 1:3 dilution series set up on each 
plate and incubated for 1 h at room temperature following incu-
bation for 1 h with anti-nurse shark IgNAR mouse monoclonal 
antibody GA8 (28) (1:500 in PBST). The plates were incubated 
for a final time with anti-mouse IgG-HRP (SIGMA) diluted 
1:1,000 in PBST. After each step, the ELISA wells were washed 
three times with 200  µl/well PBST. Plates were developed by 
adding 100 μl/well TMB substrate (Thermo Scientific) and the 
reaction stopped with 50 μl/well 1 M H2SO4.
Building of a G. cirratum Vnar Phage 
Display library
Peripheral blood lymphocytes (PBLs) were harvested from the 
plasma of the bleed with the best IgNAR response (titer) and total 
RNA isolated using a QIAGEN kit following the manufacturer’s 
instructions. cDNA was synthesized with IgNAR transmem-
brane- (Tm 5′-TACAAATGTGGTGTACAGCAT-3′) and secre-
tory- (Sec 5′-TAGTACGACCTGAAACATTA AC-3′)-specific 
primers. Using the NEB Phusion HF PCR Master Mix protocol, 
VNAR DNA was amplified with framework (FW) nurse shark-
specific primer combinations FW1/FW4r1 or FW1/FW4r2:
FW1 5′-GAGGAGGAGGAGAGGCCCAGGCGGCCG 
CTCGAGTGGACCAAACACCG-3′
FW4r1 5′-GAGGAGGAGGAGGAGGCCCCTGAGGCCG 
CATTCACAG TCACGACAGTGCCACCTC-3′
FW4r2 5′-GAGGAGGAGGAGGAGGCCCCTGAGGCCGCA 
TTCACAGTCACGGCAGTGCCATCTC-3′.
Amplicons were cloned into an in-house phage display vector 
(pEDV1) with in-frame 6xHis-tag and c-myc-tag via SfiI restric-
tion sites. The library was transformed into electrocompetent TG1 
cells (Lucigen), and the library size was calculated as described by 
Müller et al. (29).
Vnar Phage Display library screening
To rescue phage to be used in library selections, cultures from 
library glycerol stocks were grown at 37°C and 250 rpm, in 2xTY, 
2% glucose, 100 µg/ml ampicillin to an OD600 of 0.5. Cells were 
superinfected with 109 M13K07 helper phage (NEB) and then 
incubated overnight in 2xTY, 100  µg/ml ampicillin, 50  µg/ml 
kanamycin at 25°C and 250  rpm. The cultures were PEG-
precipitated (20% (w/v) PEG/2.5 M NaCl) twice, and the resulting 
phage pellets were resuspended in 1 ml PBS. To establish antigen 
“decorated” bead selections, recombinant ICOSL-flag-His pro-
tein was biotinylated with Sulfo-NHS-LC-Biotin as per manu-
facturer’s instructions (21327, Thermo Scientific). Two hundred 
microliters of magnetic Dynabeads M-280 Streptavidin (11205D, 
Invitrogen), pre-blocked with 2% (w/v) MPBS, were coated with 
50–200 nM biotinylated material by rotating at 20 rpm, at room 
temperature for 1  h. Library phage was incubated first with 
Dynabeads for 1 h rotating at room temperature to remove phage 
specific to the beads and added then to the antigen-coated beads. 
After 1 h incubation at room temperature at 20 rpm, beads with 
bound phage were washed 5–10 times with PBST and 5–10 times 
with PBS, eluted by rotating for 8 min in 400 µl 100 mM TEA 
and neutralized by the addition of 200 µl 1 M Tris-HCl pH 7.5. 
Escherichia coli TG1 cells (10 ml) were infected with 300 µl of 
eluted phage for 30  min at 37°C and grown overnight at 37°C 
on TYE agar plates containing 2% (w/v) glucose and 100 µg/ml 
ampicillin. Two further rounds of selection were conducted, and 
outputs were screened for antigen-specific binding by monoclonal 
phage and periplasmic extract ELISAs against human or mouse 
ICOSL. Phage binders were detected using HRP-conjugated 
anti-M13 antibody (27942101, GE Healthcare), and periplasmic 
protein was detected using HRP-conjugated anti-c-Myc antibody 
(118 141 50 001, Roche).
expression and Purification of Monomeric 
Vnar and Vnar Fc-Fusion Proteins
To express monomeric VNARs, non-amber-suppressor HB2151 
E. coli cells were used. VNARs were isolated from periplasm by 
osmotic shock with 50 mM Tris/HCl pH8.0, 1 mM EDTA, 20% 
sucrose and purified via His-tag capture on NiNTA resin. VNARs 
were eluted with 0.5 M imidazole pH 8.0 followed by dialysis in 
PBS. Selected positive monomeric VNAR domains were PCR 
amplified and subcloned into an in-house Fc-fusion mammalian 
expression vector (pEEE2A), which facilitated Protein A affin-
ity purification of expressed protein post transient expression 
in a HEK 293 suspension culture. HEK cells at ~106 cells/ml in 
GIBCO FreeStyle 293 media were transiently transfected using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
protocol. Twenty four hours post transfection, tryptone (0.5% 
w/v) in PBS was added to the culture to enhance expression and 
the cells incubated for 5 days. Cells were pelleted at 1,000 × g for 
15 min and the supernatants sterile filtered before adding PROSEP 
A resin (Millipore). After washing with PBS, fractions of purified 
VNAR Fc were eluted with 0.1 M glycine pH 3.0 (Severn Biotech 
Ltd.) and neutralized by adding 1 M Tris-HCl pH 8.0. Samples 
were dialyzed using Slide-A-Lyser dialysis cassettes (Thermo 
Scientific) in PBS pH 7.4. Expression levels of VNAR Fc-fusion 
proteins were generally in the range of 50–70 mg per liter using 
serum-free media. Electrophoresis of purified protein samples 
was performed on NuPAGE 4–12% Bis-Tris gels using a MES 
buffer system (Invitrogen) in accordance with the manufacturer’s 
instructions.
cell-Based Binding
CHO cells expressing human or mouse ICOSL were grown to 
90% confluency in DMEM/F12 +  5% FBS media, in 96-well 
TaBle 1 | Schedule of in vivo treatments.
group Treatment Dose route Frequency Disease 
induction
1 Untreated n/a
2 Cyclosporin A 20 mg/kg PO SID, Day 1–
Day 28
Day 0: IRBP/
CFA, SC
3 A5-Fc 10 mg/kg IP SID, Day 1–
Day 14
Day 0: PTx, IP
n/a, not applicable; PO, oral administration; SC, subcutaneous injection; IP, 
intraperitoneal injection; SID, once daily; IRBP, interphotoreceptor binding protein; CFA, 
complete Freund’s adjuvant; PTx, pertussis toxin.
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cell culture plates (Greiner, Bio-One). Anti-human or murine 
VNARs in DMEM/F12 + 2% FBS were added to the correspond-
ing CHO cells. Following 1 h incubation at 16°C, cells were gently 
washed three times with DMEM/F12 + 2% FBS and incubated 
for 40 min at 16°C with anti-His-HRP (SIGMA) diluted 1:1000 in 
the same media. Cells were washed and developed as described 
previously.
cell-Based ligand–receptor Blocking 
assay
CHO cells expressing human ICOS receptor were grown to 90% 
confluency. A total of 20 µl at 450 ng/ml of ICOSL-hFc (rhB7-
H2/Fc—165-B7, R&D Systems or rmB7-H2/Fc—158-B7, R&D 
Systems) was preincubated for 1 h with 40 µl of serially diluted 
anti-ICOSL-VNAR-Fc in DMEM/F12 + 2% FBS and then added 
to the cells. Following 1 h incubation at 16°C, cells were gently 
washed three times with DMEM/F12 + 2% FBS and incubated for 
40 min at 16°C with goat anti-human Fc-HRP (SIGMA) diluted 
1:10,000 in the same media. Cells were washed and developed as 
described previously. The absorbance was measured at 450 nm 
wavelength using a microplate reader and data were plotted using 
Sigma Plot software.
Vnar Binding elisa
96-well flat bottom Maxisorp Nunc Immuno plates (Thermo 
Scientific) were coated at 4°C overnight with 1  µg/ml of the 
antigen of interest: for monomeric VNAR binding—ICOSL-hFc 
(rhB7-H2/Fc—165-B7, R&D Systems or rmB7-H2/Fc—158-B7, 
R&D Systems), human ICOSL-IgV, mouse ICOSL-IgV, human 
ICOSL-IgC, or mouse ICOSL-IgC (all ICOSL-Igs were produced 
in-house) and for VNAR-Fc binding—human or mouse recom-
binant ICOSL-flag-His (produced in-house). The plates were 
washed three times with 200  µl/well PBS before blocking with 
200  µl of 4% (w/v) MPBS/well and incubated at 37°C for 1  h. 
The blocked plates were washed three times with PBS and serial 
dilutions of VNAR proteins were then added per designated well 
and the plates incubated at room temperature for 1 h. Plates were 
washed three times with PBST before 100 µl of 1:1,000 dilution 
HRP-conjugated anti-His or goat anti-human IgG antibody (for 
Fc-fused VNAR detection) was added to the plates and incu-
bated for 1 h at room temperature. The plates were washed and 
developed by adding 100 µl TMB substrate solution and stopped 
using 1 M H2SO4 as previously described. The absorbance was 
measured at 450 nm wavelength using microplate reader and data 
were plotted using Sigma Plot software.
Kinetic and affinity Measurements  
of Vnar-Fc
The kinetic constants of VNAR-Fc were determined by surface 
plasmon resonance using Biacore T200 and 2000 biosensors 
(GE Healthcare). Anti-human IgG1 antibody diluted in 10 mM 
sodium acetate buffer was immobilized on a CM5 chip, and 
VNAR-Fcs were captured via their Fc region. HuICOSL-flag-His 
(100 nM) was serially diluted two-fold in HEPES running buffer 
(HBS EP+, BR-1006-69, GE Healthcare) with 150  mM NaCl, 
3  mM EDTA and 0.05% v/v Surfactant P20 pH 7.4, and was 
injected for 2 min at a flow rate of 60 µl/min. Dissociation phase 
was monitored for 5  min followed by two 10  µl regeneration 
pulses using 10 mM glycine pH 1.5, at a flow rate of 100 µl/min. 
Association and dissociation rates were calculated using the 1:1 
global Langmuir binding model fit analysis (Biacore Evaluation 
Software).
Murine Model of eaU
Adult female C57BL/6 mice were randomly allocated to experi-
mental groups and allowed to acclimatize for 1 week. Treatments 
were administered according to the schedule below (Table  1). 
Test articles were administered in PBS. On Day 0, animals were 
administered with an emulsion containing 500  µg of IRBP 
peptide 1-20 (IRBP p1-20) in CFA supplemented with 2.5 mg/ml 
Mycobacterium tuberculosis H37 Ra by subcutaneous injection. 
Also on Day 0, animals were administered with 1.5 µg Bordetella 
pertussis toxin by intraperitoneal injection.
From Day 7 until the end of the experiment on Day 28, animals 
were monitored once per week for clinical signs of uveitis using 
topical endoscopic fundal imaging (TEFI) (Table  2). Animals 
were also monitored twice weekly for signs of ill-health, weighed 
and any abnormalities recorded. At termination on Day 28, eyes 
were removed into tissue fixative for histopathology.
corneal Penetration
Wild-type mice BALB/C were divided into three groups of two 
animals each. All procedures were performed on anesthetized 
animals. Corneal epithelium of the right eye was scratched and 
20 µg/3 μl of VNAR, VNAR Fc, or mAb AF158 (R&D) was applied 
four times topically to the right eye at 5-minute intervals. The eye 
was then washed with saline solution and 2 µl of anterior fluid 
sampled. All animal studies were carried out under the Animals 
(Scientific Procedures) Act 1986 regulations (Home Office UK). 
For ELISA, 96-well flat bottom Maxisorp Nunc Immuno plates 
(Thermo Scientific) were coated with 1 µg/ml of rmB7-H2/Fc or 
mICOSL-flag-His at 4°C overnight. The plates were washed three 
times with 200 µl/well PBS before blocking with 200 µl of 4% (w/v) 
MPBS per well and incubated at 37°C for 1 h. The blocked plates 
were washed three times with PBS, 100 µl of anterior fluid (start 
dilution 1:50 in PBS, then serial dilutions 1:2) was then added and 
incubated at room temperature for 1 h. Plates were washed three 
times with PBST and 100 µl of 1:1,000 dilution HRP-conjugated 
anti-His (for VNAR detection) or goat anti-human IgG antibody 
(for Fc-fused VNAR and mAb detection) was added to the plate 
TaBle 2 | Clinical score ranking using topical endoscopic fundal imaging.
clinical 
score
Optic disk 
inflammation
retinal vessels retinal tissue infiltration structural damage
1 Minimal 1–4 mild cuffings 1–4 small lesions or 1 linear lesion Retinal lesions or atrophy involving 1/4–3/4 of retinal area
2 Mild >4 mild cuffings or 1–3 
moderate cuffings
5–10 small lesions or 2–3 linear lesions Panretinal atrophy with multiple small lesions (scars) or ≤3 linear 
lesions (scars)
3 Moderate >3 moderate cuffings >10 small lesions or >3 linear lesions Panretinal atrophy with >3 linear lesions or confluent lesions 
(scars)
4 Severe >1 severe cuffings Linear lesion confluent Retinal detachment with folding
5 Not visible (white-out or severe detachment)
5
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and incubated for 1  h at room temperature. The plates were 
washed and developed by adding 100 µl TMB substrate solution 
and stopped using 1 M H2SO4 as previously described.
resUlTs
Vnar library construction from 
immunized nurse shark
Two nurse sharks were immunized with both recombinant 
human and mouse ICOSL. An antigen-specific IgNAR immune 
response was observed and confirmed after 18 weeks through 
the analysis of post-immunized sera. The response was exem-
plified by a gradual increase in titer values from early to late 
bleeds (data not shown). The VNAR repertoire was amplified 
from isolated PBLs, cloned into a pEDV1 which contained an 
in-frame coat protein pIII of the bacteriophage M13 gene and 
transformed into E. coli TG1 cells. The library size was calculated 
to be 108 transformants.
isolation of human icOsl-specific Vnars
Domains were isolated following three rounds of selection utiliz-
ing biotinylated antigen immobilized on streptavidin-coated 
beads to maximize the chance of delivering potent ICOSL binders 
(30). huICOSL-specific VNARs were obtained after the first selec-
tion round and enriched further after round three with >90% 
of domains specific for antigen (Figure 1A). As blockade of the 
ICOS–ICOSL interaction was the desired functional outcome 
of the selection process, a cell-based assay designed to detect 
domains that can block receptor/ligand binding was introduced 
into the screen. Positive hits from selections against huICOSL 
were assessed for their ability to block huICOSL binding to ICOS 
expressing cells (Figure  1C). Signals that decreased by 50% or 
more were considered positive for receptor–ligand binding 
inhibition. In total, six unique (based on CDR3 sequence differ-
entiation) anti-human ICOSL VNAR clones were identified. Cell 
surface antigen-target selectivity was assessed by FACS analysis 
utilizing CHO cells overexpressing human or murine ICOSL (data 
not shown) as well as in a binding ELISA format (Figure 2A). 
All domains were found to be strong huICOSL binders but with 
no species cross-reactivity to the mouse ligand. The affinity of 
huICOSL binders was in the range 1–9 nM (Table 3). ICOSL is 
a two-domain protein, where receptor binding is mediated solely 
by the membrane distal IgV domain but requires the membrane 
proximal IgC domain to maintain the structural integrity of 
the protein (31). All of the isolated blocking huICOSL VNARs 
cross-reacted strongly with the ICOSL-IgV domain with weaker 
or negligible binding to the ICOSL-IgC domain (Figure 2B). As 
the percentage homology between the human and murine IgV 
region of ICOSL is only 43%, it was not surprising that the screen 
did not isolate species cross-reactive VNARs that block receptor/
ligand interaction.
isolation of Mouse icOsl-specific Vnars
Anti-mouse ICOSL VNAR domains were isolated using the 
same method as for the anti-human domains and lead clone 
isolation determined following their performance in in  vitro 
(Figure  1B) and cell-based binding assays. Four unique binders, 
all within an EC50 (effective concentration) range from 1.4 to 
11.4  nM (Figure  3A), were taken forward for further study. 
Three of these anti-mICOSL clones (A5, A7, and B8) could block 
ligand/receptor binding in a CHO-cell-based blocking assay, 
whereas clone F11 lacks this blocking activity and was used here 
as a non-blocking control (Figure 3B). The naïve VNAR domain 
2V was also included as an isotype control in ligand/receptor 
binding assays. This clone originally isolated from the dogfish 
(Squalus acanthias) is part of a sequence database from this spe-
cies and has no known target, making it an ideal negative control 
for these and other studies (11).
specificity of anti-micOsl Vnars
Unlike VNARs obtained from the human ICOSL selection 
campaign, domains isolated from mouse ICOSL selections were 
species cross-reactive. Three of the four clones recognize both 
mouse and human ligand in an ELISA with clear binding to IgC 
domains (Figures 3C,D). Interestingly, clone A5, which was the 
strongest ICOS/ICOSL blocker (Figure 3B), bound only to the 
full length mouse protein, but not to the individual IgV and IgC 
domains implying that it may recognize an interdomain or link-
ing region between them (Figure 3C).
Fc-reformatting of anti-micOsl Vnars
A key aim of this work was to determine the efficacy of VNAR 
domains in an in vivo mouse model. As VNAR domains alone 
are cleared rapidly from the systemic circulation (11), all VNAR 
clones were first converted into a fusion format with a human 
Fc (Figure  4A) to facilitate an extension of serum half-life. 
All VNAR Fcs retained binding to mICOSL with improved, 
presumably through avidity, EC50s in the range 0.6 to 3  nM 
FigUre 1 | Continued
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FigUre 2 | Characterization of anti-huICOSL lead domains binding. (a) Lead anti-huICOSL VNAR domains were tested for binding to human and mouse ICOSL  
in ELISA. (B) Binding of lead clones to the IgC and/or IgV domain of the ICOS ligand.
FigUre 1 | Continued  
Selection of anti-ICOSL VNARs. (a) Screening of outputs from a selection campaign with human ICOSL. The scatter plot represents screening data of phage 
monoclonals from each round of selection for specific binding to huICOSL (Y axis) vs non-specific binding to human serum albumin (X axis). Each circle denotes a 
single clone. (B) Screening of outputs from a selection campaign with mouse ICOSL. The scatter plot represents screening data of phage monoclonals from each 
round of selection for specific binding to mICOSL (Y axis) vs non-specific binding to human serum albumin (X axis). (c) Cell-based binding and huICOS-huICOSL 
blocking assay. Monoclonal VNAR outputs from third round of selection with huICOSL were expressed in periplasm, and periplasmic fractions were tested in 
cell-based binding and ICOS-ICOSL blocking assays. The X axis indicates CHO-huICOSL binding with higher signals corresponding to stronger binders and the Y 
axis identifies clones with decreased signals that are capable of blocking the interaction of ICOSL with CHO-huICOS. The circled area captures all clones which are 
both strong huICOSL binders and can block ICOS/ICOSL interaction. The human ICOSL positive control is the mouse monoclonal anti-huB7-H2 antibody  
(MAB165, R&D).
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(Figure  4B). In cell-based ICOS/ICOSL blocking assays con-
ducted with Fc-reformatted VNAR domains, clone A7, which 
performed well as a monomeric VNAR, lost this ability after 
Fc-fusion (Figure 4C). The reason for the loss of activity was not 
investigated further at this time. In summary, A5-Fc and B8-Fc, 
both blocked receptor/ligand interaction, did not bind human 
ICOS ligand but did bind mouse and rat protein. F11-Fc did not 
block ICOS/ICOSL binding, and A7-Fc, which lost its blocking 
ability after reformatting, bound ligands from all three species 
(Figure 4D).
FigUre 3 | Binding specificity of anti-mICOSL lead domains and blocking of ligand/receptor interaction. (a) Binding to mouse ICOSL. Titration curves of four lead 
anti-mICOSL domains binding to recombinant mouse ICOSL in ELISA and calculated EC50 values. (B) Blocking of ligand/receptor binding. Concentration-dependent 
inhibition of mICOSL-Fc binding to cell surface expressed hICOS by the addition of serial dilutions of anti-mICOSL VNAR domains (from 30 to 500 nM). 2V is the 
VNAR isotype control used in this experiment. (c) Binding to the IgC and IgV domains of the mouse ICOSL. (D) Binding to IgC and IgV part of the human ICOSL.
TaBle 3 | Kinetic parameters and affinity determination of VNAR-Fcs binding to 
human ICOSL.
Vnar-Fc ka (1/Ms) kd (1/s) KD (M) 
VNAR 1 3.11 × 105 9.51 × 10−4 3.06 × 10−9
VNAR 2 5.50 × 105 6.69 × 10−4 1.22 × 10−9
VNAR 3 5.96 × 105 1.00 × 10−3 1.68 × 10−9 
VNAR 4 8.73 × 105 3.93 × 10−3 4.50 × 10−9
VNAR 5 3.73 × 105 4.15 × 10−3 1.11 × 10−8
VNAR 6 3.26 × 105 2.73 × 10−3 8.39 × 10−9 
Isotype control 2V Did not bind
Kinetic measurements of anti-huICOSL domains. Kinetic analysis of six anti-huICOSL 
lead domains is summarized in the table. The interaction between the lead clones and 
huICOSL was measured by surface plasmon resonance (SPR). An anti-human IgG 
antibody was immobilized on a Biacore chip and the VNAR clones captured via their 
Fc region.
ka—association rate constant; kd—dissociation rate constant; KD—binding affinity.
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evaluation of anti-micOsl Vnars  
in a Murine Model of eaU
The lead domain A5-Fc was assessed in a murine model of 
EAU by KWS (Bristol, UK). Adult female C57BL/6 mice were 
randomly allocated to experimental groups and allowed to 
acclimatize for 1 week. Treatments were administered according 
to the protocol described in Section “Materials and Methods” 
from Day 1 to Day 14 or Day 1 to Day 28 for the corticosteroid 
control (five mice per group) and from Day 1 to Day 14 for the 
A5-Fc protein (six mice per group). On Day 0, animals were 
administered with IRBP p1-20 in CFA supplemented with 
M. tuberculosis H37 Ra to induce uveitis. All animals were 
weighed three times a week and also monitored twice weekly for 
signs of ill-health and any abnormalities recorded. The disease-
induction procedure (subcutaneous administration of IRBP/
CFA and intraperitoneal injections of pertussis toxin) caused a 
mild bodyweight loss on Day 2 and Day 5, as expected for this 
model. However, from day 7 until the end of the experiment, 
there was no further treatment-induced bodyweight loss in any 
of the experimental groups (Figure 5A). From day 7 until the 
end of the experiment, animals were monitored once a week 
for clinical signs of uveitis using TEFI. A significant increase in 
TEFI scores was observed on Day 21 when compared with the 
untreated Day 7 control group. By day 21, both the Cyclosporin 
A and the anti-mICOSL VNAR domain A5-Fc groups showed 
a significant reduction in recorded clinical scores and a marked 
lag in the onset of any disease when compared to the untreated 
FigUre 4 | Characterization of anti-mICOSL lead domains after Fc reformatting. (a) SDS-PAGE of HEK293 expressed VNAR Fc. (B) Binding to mouse ICOSL. 
Titration curves of anti-mICOSL-Fc domains binding to recombinant mouse ICOSL. (c) Blocking of ligand/receptor binding. Concentration-dependent inhibition  
of recombinant mICOSL-Fc binding to cell surface expressed hICOS by the addition of serial dilutions of anti-mICOSL-Fc domains. 2V-Fc is the isotype control.  
(D) Species cross-reactivity of anti-mICOSL-Fc domains.
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control animals (Figure  5B). Histopathology analyses of eyes, 
removed at the end of the experimental period (Day 28), con-
firmed that this observed reduction in inflammation translated 
into differences at the tissue level too (Figure 5C). Furthermore, 
detailed cellular observation clearly showed that animals treated 
with either Cyclosporin A or with anti-mICOSL VNAR domain 
A5-Fc presented with mild disease pathology compared to 
the untreated control. The control animals exhibited extensive 
cellular inflammation with a high number of neutrophilic cells 
accumulating in the vitreous, the drainage angle, the anterior 
chamber, the ciliary body and also in the surrounding blood 
vessels (Figure 5D).
corneal Penetration of Vnar
The influence of molecular size on the ability of biologics to enter 
the eye if applied topically was assessed in a scratched corneal 
mouse model that goes some way to mimicking the situation 
seen in severe inflammatory eye conditions. It was hoped that the 
smaller size of the VNAR domains may provide a delivery option 
for site-specific targeting of ocular disorders. Three formats of 
increasing molecular weight were tested: VNAR single domains 
(11 kDa), VNAR Fc (80 kDa) and mAb (150 kDa). All three were 
applied dropwise onto cornea without an epithelium and anterior 
fluid was collected after 20  min of treatment. The presence of 
VNAR was clearly observed in the anterior fluid compared to 
VNAR-Fc and mAb (Figure 6).
DiscUssiOn
Uveitis, a major cause of severe visual loss around the world, 
may be idiopathic or occur as a part of systemic disease such as 
spondyloarthritis, Vogt–Koyanagi–Harada syndrome, sar-
coidosis, autoimmune hepatitis, systemic lupus erythematosus 
and multiple sclerosis (32). First-line therapy for patients with 
active uveitis is corticosteroids because of their rapid effect and 
the flexibility in the choice of their delivery—locally to the eye 
or systemically. However, long-term corticosteroid treatment 
is associated with the risk of various adverse events including 
cataract, glaucoma, diabetes, cushingoid changes, hypercho-
lesterolemia and osteoporosis (33). If a desired response is 
not achieved with short-term therapy and/or corticosteroids 
fail to control the inflammation, biological agents may be 
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required for the treatment of worsening or refractory disease. 
Immunomodulatory biologics are powerful drugs that have 
been used to treat immune-related diseases in a number of dif-
ferent therapeutic areas. They can be designed to dampen down 
hyperimmune responses and therefore have utility in chronic 
autoimmune and inflammatory conditions (21). However, it is 
well known that the prolonged use of powerful systemic biolog-
ics can also result in the development of significant off-target 
side effects and patient complications.
Like the development of many drugs, biologics often rely upon 
animal models as predictors of clinical efficacy. However, due to 
the inherent high target specificity of biologics and in some cases 
low target homology across species, the use of rodent models for 
preclinical efficacy and safety studies is sometimes precluded. 
When this situation occurs it is common practice to develop a 
surrogate or analogous candidate (e.g., for anti-TNF clinical 
biologics development) that targets the orthologous protein in 
rat or mouse (34–38). Here, anti-mICOSL VNAR domains could 
FigUre 5 | Clinical scores and histopathology sections from the interphotoreceptor retinoid-binding protein-induced uveitis study. (a) Bodyweights. All 
animals were weighed three times a week. Data are presented as mean ± SEM of percentage initial (Day 0) bodyweights. No bodyweight loss was observed. 
(B) Clinical scores. Retinal imaging by topical endoscopic fundal imaging (TEFI) was analyzed by one-way ANOVA followed by Dunn’s test for multiple 
comparisons between experimental days. A significant increase in TEFI scores was observed on Day 21 when compared to Day 7 in the untreated group, as 
expected for this model of uveitis. Cyclosporin A, administered from Day 1 until the end of the experiment, induced a significant reduction in the clinical scores 
when compared to the untreated group at Day 21. A5-Fc, administered from Day 1 until Day 14 of the experiment, delivered a comparable result to the 
Cyclosporin A group treated for 28 days. (c) Histopathology scores. Histopathology scores were analyzed by the Kruskal–Wallis test followed by Dunn’s 
post-test for multiple comparisons between experimental groups. The pathological changes observed were consistent with those reported for the model. 
Greater inflammation was observed in Group 1 (untreated). Cyclosporin A administered from Day 1 until Day 28 and A5-Fc administered from Day 1 until Day 
14 caused an equivalent reduction in the histopathology scores. (D) Histopathology sections. Dissected eyes were embedded in paraffin wax, sectioned, and 
stained with hematoxylin and eosin for detailed histopathology analysis at the cellular level. (1) Healthy entire eye glob section and normal retina. (2) Untreated 
(=uveitis): inflammatory cells in the vitreous (upper panel), a cuff of inflammatory cells surrounding the vessel (middle panel) and neutrophilic inflammation in the 
drainage angle, anterior chamber, and ciliary body (lower panel). (3) Cyclosporin A treated: mild inflammation of the vitreous (upper and middle panels) and mild 
vasculitis (lower panel). (4) A5-Fc treated: a low number of inflammatory cells (mild inflammation) in the vitreous (above and middle panels) and mild vasculitis/
cuffing (lower panel).
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be considered surrogates for the use of anti-hICOSL VNARs in 
patient therapy. In this study, we have isolated anti-mouse and 
anti-human VNARs from a nurse shark immunized library that 
can inhibit the receptor/ligand interaction and demonstrated for 
the first time the efficacy of an anti-mICOSL VNAR domain in a 
clinically relevant mouse model of EAU. The EAU model is well 
characterized and widely used as a clinical model of human non-
infectious uveitis (39, 40). ICOSL and its importance in antibody-
mediated human disease have been verified in a number of 
preclinical models including RA, SLE and uveitis (22–24, 41–44). 
The effectiveness of using a mouse mAb to block the interaction 
between ICOS-ICOSL has also previously been demonstrated in 
EAU (43).
Shark VNAR domains have been previously isolated against 
a number of targets from both semisynthetic and immunized 
sources (10, 11, 19, 45–52). The first demonstration of in vivo 
VNAR activity showed that an anti-HSA VNAR domain 
isolated from an immunized dogfish could extend the serum 
half-life of a fused partner VNAR across mouse, rat and monkey 
pharmacokinetic models (11). In later work, a single anti-TNFα 
VNAR domain was isolated from an immunized horn shark 
and showed a modest level of inhibition in a murine model 
of endotoxic shock (53). Most recently, the isolation of B cell-
activating factor-specific VNAR from a synthetic library was 
shown to function as selective B-cell inhibitors to target B-cell 
disorders (52). However to date, this uveitis study is the first 
example of a VNAR domain showing significant in vivo efficacy 
in a recognized clinical model, establishing the potential for the 
future development of human-specific surrogates as effective 
treatments of autoimmune disease.
Current advances in ocular drug delivery technologies, 
suitable for the administration of smaller molecular weight 
biologics (54–56), provide an encouraging future for the use 
of VNARs (or their humanized equivalents) in ophthalmology 
and offer the promise of effective site-specific and systemic side 
effect-free delivery. At 11 kDa, VNARs are the smallest domains 
of their type in the animal kingdom and are almost 13 times 
smaller than an antibody, making the delivery of VNAR to 
the back of the eye more achievable. We have presented here 
preliminary evidence that VNAR, if applied topically and at high 
concentrations, can cross the cornea and be found in the anterior 
chamber of a mouse eye, whereas an mAb or VNAR-Fc could 
not. The amounts delivered appeared to reflect the molecular 
weight of the formats tested with VNAR Fc observed in anterior 
fluid but at much lower concentrations compared to the single 
VNAR. It is therefore attractive to speculate that combining 
the benefits of VNAR domains with a validated inflammatory 
disease target and new drug delivery technologies could result 
in the development of a viable drug candidate for ocular disease 
treatment that could be administered either systemically and/
or site-specifically.
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FigUre 6 | Corneal penetration of VNAR, VNAR Fc, and mAb. A mouse eye 
with a scratched cornea (to remove epithelium) was treated for 20 min with 
VNAR (two animals), VNAR-Fc (two animals), or mAb (two animals) by 
applying drops (4 × 3 µl) directly onto the eye. Anterior fluids were collected 
and analyzed in ELISA for the presence of VNAR, VNAR Fc, or mAb. VNAR, 
but not mAb or VNAR-Fc, was detected in anterior fluid of both mice.
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